UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)

被引：0

作者：

Gullick, G. ^{[1
]}

Owen, C. ^{[2
]}

Cook, S. ^{[3
]}

Helbrow, J. ^{[4
]}

Squires, R. ^{[1
]}

Reed, H. M. ^{[1
]}

Park, S.

Weir, E. ^{[5
]}

Aquilina, F. ^{[5
]}

Webber, N. ^{[6
]}

Nye, E. ^{[6
]}

Atkinson, C. ^{[3
]}

Blair, C. ^{[1
]}

Halstead, A. ^{[1
]}

Daniels, E. ^{[4
]}

Alves, A. ^{[1
]}

Chew, S. ^{[5
]}

Thomas, W. ^{[4
]}

Spensley, S. ^{[3
]}

Robinson, T. ^{[2
]}

机构：

[1] Bristol Canc Inst, Med Oncol Dept, Bristol, England

[2] Univ Bristol, Fac Hlth Sci, Bristol Med Sch, Bristol, England

[3] Taunton & Somerset NHS Fdn Trust, Oncol Dept, Musgrove Pk Hosp, Taunton, England

[4] Gloucestershire Hosp NHS Fdn Trust, Oncol Dept, Gloucestershire Oncol Ctr, Cheltenham Gen Hosp, Cheltenham, England

[5] NHS Royal Devon Univ Healthcare, Oncol Dept, Royal Devon & Exeter Hosp Wonford, Exeter, England

[6] Royal United Hosp Bath NHS Fdn trust, Oncol Dept, Bath, England

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.598

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

422P

引用

页码：S360 / S360

页数：1

共 50 条

[41] REAL-WORLD RELATIVE DOSE INTENSITY IN PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER TREATED WITH CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN SWEDEN
Siljander, L.
Moller, Holmen A.
Hornemann, Toft A.
VALUE IN HEALTH, 2022, 25 (12) : S449 - S449
[42] A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status
Untch, Michael
Fasching, Peter Andreas
Mclaurin, Kimmie
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 11 - 11
[43] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
Micha, John P.
Rettenmaier, Mark A.
Bohart, Randy D.
Goldstein, Bram H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 547 - 551
[44] PHARMACEUTICAL INHIBITION OF CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) IN GLIOBLASTOMA
Nuga, Oluwademilade
Meng, Yuling
Berezovsky, Artem
Nelson, Kevin
deCarvalho, Ana
NEURO-ONCOLOGY, 2020, 22 : 94 - 95
[45] TREATMENT PATTERNS INCLUDING ADHERENCE/PERSISTENCE WITH CYCLIN-DEPENDENT KINASE 4&6 INHIBITORS (CDK4&6I) AMONG US COMMERCIALLY INSURED WOMEN WITH METASTATIC BREAST CANCER (MBC)
Singhal, M.
Nepal, B.
Fisch, M. J.
Debono, D.
Grabner, M.
Stephenson, J. J.
Churchill, C.
Gable, J.
Zhu, Y.
Stenger, K.
Carter, Cuyun G.
VALUE IN HEALTH, 2020, 23 : S462 - S462
[46] BIOMARKERS RELATED TO SURVIVAL BENEFIT IN THE TREATMENT OF METASTATIC LUMINAL BREAST CANCER (mBC) WITH CYCLIN 4/6 INHIBITORS (CDK 4/6i) PLUS ENDOCRINE THERAPY (ET)
Murillo, Serafin Morales
Cudos, Ariadna Gasol
Der-Abrain, Noemi Tuset
Urdanibia, Izaskun
Galindo, Alvaro Rodriguez
Sanchez, Ana Velasco
Villellas, Felip Vilardell
Guzman, Douglas Sanchez
Morales, Carles Canosa
Olive, Jordi Mele
Cid, Laura Arbones
CANCER RESEARCH, 2023, 83 (05)
[47] Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
Tamura, Kenji
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 993 - 998
[48] Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer
Anampa, Jesus
Haque, Tamanna
Murakhovskaya, Irina
Wang, Yanhua
Bachiashvili, Kimo
Papazoglu, Cristian
Pradhan, Kith
Steidl, Ulrich G.
Sparano, Joseph A.
Verma, Amit
HAEMATOLOGICA, 2018, 103 (03) : E98 - E102
[49] Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer
Nina, Privsek
Cvetka, Grasic Kuhar
ONKOLOGIJA, 2021, 25 (02) : 48 - 53
[50] Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
Nwabudike, Stanley Madu
Edwards, Camille V.
Akinboro, Oladimeji
Quinn, Kathryn
Sarosiek, Shayna
Ko, Naomi
CASE REPORTS IN HEMATOLOGY, 2018, 2018

← 1 2 3 4 5 →